Abstract Number: 341 • 2019 ACR/ARP Annual Meeting
Development of a Multivariable Improvement Measure for Gout
Background/Purpose: Gout is a multifactorial inflammatory disease in which patients experience a wide range of signs and symptoms, including flares, inflammatory arthritis, tophi and disability.…Abstract Number: 356 • 2019 ACR/ARP Annual Meeting
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Background/Purpose: Urate lowering therapy (ULT) is expected to prevent new gout flares. Treat-to-target ULT is however often not performed, and more evidence on how often…Abstract Number: 767 • 2019 ACR/ARP Annual Meeting
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…Abstract Number: 1655 • 2019 ACR/ARP Annual Meeting
Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: The association between systemic sclerosis (SSc) skin histology and clinical findings is not fully characterized. In two SSc trials, we developed a scoring system…Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…Abstract Number: 2840 • 2019 ACR/ARP Annual Meeting
Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare, debilitating systemic diseases characterized by proximal muscle weakness, which limit activities of daily living and…Abstract Number: 481 • 2018 ACR/ARHP Annual Meeting
Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis
Background/Purpose: The use of physical activity monitors (PAM), which objectively quantify free-living movement, may enhance assessment of disease activity in juvenile myositis (JM) clinical trials…Abstract Number: 2687 • 2018 ACR/ARHP Annual Meeting
Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors
Background/Purpose: Treatment benefit is demonstrated by evidence that interventions have positive impacts on how patients feel, function, and/or survive (FDA Guidance, 21CFR314.510). The ACR CRISS,…Abstract Number: 681 • 2018 ACR/ARHP Annual Meeting
Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that affects the skin, joints, and soft tissues. No metrics exist to indicate whether an…Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting
EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases
Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…Abstract Number: 723 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Cognitive Screen Does Not Identify Cognitive Sub-Domains: Exploration of the Subscale Structure of the Perceived Deficits Questionnaire in a Systemic Lupus Erythematosus Cohort
Background/Purpose: Identifying patients with Systemic Lupus Erythematosus related cognitive impairment (SLE-CI) is critical as SLE-CI can negatively affect employment, quality of life, and disease self-management.…Abstract Number: 2857 • 2018 ACR/ARHP Annual Meeting
An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Background/Purpose: The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study of US Veterans with RA at 11 VA Medical…Abstract Number: 1261 • 2018 ACR/ARHP Annual Meeting
Development a Core Domain Set to Assess Shared Decision Making Interventions in Rheumatology: An OMERACT White Paper to Facilitate Endorsement
Background/Purpose: Shared decision making (SDM) improves decisional outcomes and patient-physician communication and holds great potential for improving the management of various rheumatology conditions. However, the…Abstract Number: 2871 • 2018 ACR/ARHP Annual Meeting
Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis
Background/Purpose: We have previously reported an evaluation of 941 US Veterans in the Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry that 559 (59%)…Abstract Number: 1446 • 2018 ACR/ARHP Annual Meeting
The Optimal Joint Set for Ultrasound Assessment of Synovitis in RA: Results from the Rasch Measurement Model
Background/Purpose: The recently introduced composite OMERACT-EULAR power Doppler (PD)/grey scale (GS) ultrasound (PDUS) scoring system for RA with a proposed 18 joint set was developed…
- 1
- 2
- 3
- …
- 12
- Next Page »